Marshall Wace’s InfuSystem Holdings INFU Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.45M Buy
265,209
+121,430
+84% +$1.06M ﹤0.01% 1668
2025
Q4
$1.29M Sell
143,779
-40,524
-22% -$388K ﹤0.01% 1800
2025
Q3
$1.91M Buy
184,303
+78,415
+74% +$651K ﹤0.01% 1647
2025
Q2
$661K Buy
105,888
+32,069
+43% +$177K ﹤0.01% 2039
2025
Q1
$397K Buy
73,819
+20,504
+38% +$150K ﹤0.01% 2168
2024
Q4
$451K Buy
53,315
+32,015
+150% +$252K ﹤0.01% 2078
2024
Q3
$143K Buy
21,300
+2,053
+11% +$13.3K ﹤0.01% 2337
2024
Q2
$131K Buy
+19,247
New +$141K ﹤0.01% 2372
2023
Q2
Sell
-16,390
Closed -$127K 2692
2023
Q1
$127K Sell
16,390
-4,870
-23% -$44.9K ﹤0.01% 2471
2022
Q4
$185K Sell
21,260
-12,339
-37% -$101K ﹤0.01% 2712
2022
Q3
$235K Buy
33,599
+2,625
+8% +$22K ﹤0.01% 3036
2022
Q2
$299K Buy
30,974
+15,336
+98% +$134K ﹤0.01% 3031
2022
Q1
$154K Buy
+15,638
New +$201K ﹤0.01% 3141
2021
Q1
Sell
-11,564
Closed -$217K 2653
2020
Q4
$217K Sell
11,564
-6,233
-35% -$93.9K ﹤0.01% 1733
2020
Q3
$228K Buy
+17,797
New +$231K ﹤0.01% 1431

Other funds holding INFU

Marshall Wace's INFU Position: Q1 2026 in Review

Marshall Wace increased its InfuSystem Holdings (INFU) stake by 84% in Q1 2026, buying an estimated $1.06M and bringing the position to 265,209 shares worth $2.45M. The position accounts for ﹤0.01% of the portfolio, ranked #1668.

Marshall Wace first reported a position in INFU in Q3 2020 and has held it in 15 quarters since. 96 funds tracked by Wall St. Rank hold INFU as of Q1 2026.

  • Marshall Wace held 265,209 shares of InfuSystem Holdings worth $2.45M as of Q1 2026.
  • Marshall Wace bought 121,430 InfuSystem Holdings shares in Q1 2026, an estimated $1.06M.
  • InfuSystem Holdings made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #1668 holding.
  • Marshall Wace first reported a position in InfuSystem Holdings in Q3 2020 and has held it in 15 quarters since.
  • 96 funds tracked by Wall St. Rank held InfuSystem Holdings as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.